Merck Revenue 2006-2018 | MRK

Current and historical revenue for Merck (MRK) from 2006 to 2018. Revenue can be defined as the sum of all revenue fields included for a company's operating activities. Merck revenue for the twelve months ending June 30, 2018 was $41.260B. Merck revenue for the three months ending June 30, 2018 was $10.465B, representing a 5.39% increase from the same quarter last year.
Merck Annual Revenue
(Millions of US $)
2017 $40,122
2016 $39,807
2015 $39,498
2014 $42,237
2013 $44,033
2012 $47,267
2011 $48,047
2010 $45,987
2009 $27,428
2008 $23,850
2007 $24,198
2006 $22,636
2005 $22,012
Merck Quarterly Revenue
(Millions of US $)
Q2 2018 $10,465
Q1 2018 $10,037
Q4 2017 $10,433
Q3 2017 $10,325
Q2 2017 $9,930
Q1 2017 $9,434
Q4 2016 $10,115
Q3 2016 $10,536
Q2 2016 $9,844
Q1 2016 $9,312
Q4 2015 $10,215
Q3 2015 $10,073
Q2 2015 $9,785
Q1 2015 $9,425
Q4 2014 $10,482
Q3 2014 $10,557
Q2 2014 $10,934
Q1 2014 $10,264
Q4 2013 $11,320
Q3 2013 $11,032
Q2 2013 $11,010
Q1 2013 $10,671
Q4 2012 $11,737
Q3 2012 $11,488
Q2 2012 $12,311
Q1 2012 $11,731
Q4 2011 $12,294
Q3 2011 $12,022
Q2 2011 $12,151
Q1 2011 $11,580
Q4 2010 $12,094
Q3 2010 $11,125
Q2 2010 $11,346
Q1 2010 $11,422
Q4 2009 $10,093
Q3 2009 $6,050
Q2 2009 $5,900
Q1 2009 $5,385
Q4 2008 $6,032
Q3 2008 $5,944
Q2 2008 $6,052
Q1 2008 $5,822
Q4 2007 $6,243
Q3 2007 $6,074
Q2 2007 $6,111
Q1 2007 $5,769
Q4 2006 $6,044
Q3 2006 $5,410
Q2 2006 $5,772
Q1 2006 $5,410
Q4 2005 $5,766
Q3 2005 $5,416
Q2 2005 $5,468
Q1 2005 $5,362
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $178.137B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.789B 16.76
Pfizer (PFE) United States $243.651B 14.26
Novartis AG (NVS) Switzerland $190.263B 16.32
AbbVie (ABBV) United States $145.067B 14.17
Novo Nordisk (NVO) Denmark $114.528B 18.31
Eli Lilly (LLY) United States $109.815B 20.33
Sanofi (SNY) France $104.261B 13.20
AstraZeneca (AZN) United Kingdom $99.745B 10.97
GlaxoSmithKline (GSK) United Kingdom $99.569B 13.30
Bristol-Myers Squibb (BMY) United States $96.944B 17.55